Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded ...

Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes.

Novo Nordisk (NVO) is aware of 10 deaths and 100 hospitalizations of people that took copycat versions of its popular drugs ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

it took another four years for Wegovy to be approved for weight loss. It turned Novo Nordisk from niche player, to a company bigger than Coca Cola and Procter and Gamble… The CEO is Lars ...